Sysdig Usage Report Finds Shifting Container Security Left is Not Enough
Sysdig, Inc., the secure DevOps leader, today announced findings from its Sysdig 2021 Container Security and Usage Report. While usage reveals organizations are shifting left by scanning images during the build phase, DevOps teams are still leaving their environments open to attack. The report also looks at trends, finding a 310 percent growth in container density since 2017.
The fourth annual report reveals how global Sysdig customers of all sizes and across industries are using and securing container environments. This real-world, real-time data provides insight into usage of the nearly one billion containers Sysdig customers run yearly, including security risks, container utilization, and services used. Read the Sysdig 2021 Container Security and Usage blog.
Among its findings, the report states that while 74 percent of customers are scanning before deployment, still more than half (58 percent) of containers are running as root. There are some containers that should run as root—security and system daemons for example—but this is a small portion of total containers. These risky configurations leave easy access to potentially compromise the system and access sensitive data. This finding stresses the need for security throughout the lifecycle of a container image—fixing vulnerabilities is not enough.
Highlights From the Report
Container density grows 170% since 2018
Over the past three years, the median number of containers-per-host more than doubled from 15 in 2018 to 41 today, indicating a growth in efficiency and a shift in cost savings as containers mature. This reveals a continued focus on optimization.
Prometheus continues to grow, 35% YoY
Open source adoption is broader than just Kubernetes as organizations are shifting toward Prometheus as the standard approach to monitoring container environments. The use of Prometheus metrics among Sysdig customers grew 35 percent year-over-year.
Docker down, containerd and CRI-O up 4X
In 2017, Docker represented 99 percent of containers in use at that time. Today, that number has fallen to 50 percent, down from 79 percent in October 2019. While Docker revolutionized containers, organizations are rapidly switching to newer runtimes like containerd and CRI-O.
21% of containers live less than 10 seconds
The ephemeral nature of containers is a unique efficiency advantage, yet it can be a challenge in managing issues around security, health, and performance. The short life of containers reaffirms the need for container-specific tools for security and monitoring. For example, organizations need metric collection with intervals of less than 10 seconds and a detailed record of what occurred when the container was alive.
“With the high-profile breaches we are seeing and the accelerated adoption of containers in production, the container security risk is now on the radar of CISOs. Across millions of containers that we have studied, it’s clear that organizations are shifting security left, but they are neglecting critical best practices,” said Suresh Vasudevan, chief executive officer of Sysdig. “Container security has to span the entire software development lifecycle. Until organizations fix risky configurations, protect their runtime environments, and invest in container forensics, we will see an increase in container security breaches. I expect we will see several high-impact breaches before we release our next report.”
Other Interesting Findings
- Falco, the open source runtime project for cloud-native environments created by Sysdig and donated to the CNCF, has seen a 300 percent increase in Docker Hub downloads over the last year.
- The use of golang increased to 66 percent, a 470 percent jump since last year.
- 63 percent of container images are replaced within two weeks or less, signifying a more frequent code deployment rate.
Learn More About this Report
- Download the full Sysdig 2021 Container Security and Usage Report.
- Download the infographic.
- Read the usage report blog.
- Join the webinar Real-World Insights: Dig into Sysdig’s Container Security and Usage Report on Jan. 21 at 10am PST to walk through the report with the author.
About Sysdig
Sysdig is driving the secure DevOps movement, empowering organizations to confidently secure containers, Kubernetes, and cloud services. With the Sysdig Secure DevOps Platform, cloud teams secure the build pipeline, detect and respond to runtime threats, continuously validate compliance, and monitor and troubleshoot cloud infrastructure and services. Sysdig is a SaaS platform, built on an open source stack that includes Falco and sysdig OSS, the open standards for runtime threat detection and response. Hundreds of companies rely on Sysdig for container and Kubernetes security and visibility. Learn more at www.sysdig.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005319/en/
Contact information
Amanda McKinney Smith
(703) 473-4051
amanda.smith@sysdig.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 20268.12.2025 09:00:00 EET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity Incobotulinumto
Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 08:05:00 EET | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additionally, Galderma and L’Oréal aim at exploring additional scientific research projects of mutual interest. This ongoing collaboration brings together Galderma’s scientific leadership i
Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 05:37:00 EET | Press release
Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the National Institute of Standards and Technology (NIST) show that many commercial facial recognition algorithms have significantly higher error rates for women and people of colour largely due to underrepresentation in datasets AI algorithms are trained on. Biased algorithms lead to unfair denials of service and create security vulnerabilities. The competition at the Conference on Neural Information Processing Systems, among the world’s most prestigious AI con
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
